Mektovi is a medicine used in adults for treating certain cancers when their cells have a mutation (change) in their genes called 'BRAF V600'. Mektovi is used in combination with another medicine, encorafenib , to treat: * melanoma (a skin cancer) that has spread or cannot be removed by surgery; * a type of lung cancer called non\-small cell lung cancer (NSCLC). It is used when the cancer is advanced and has the BRAF V600E version of the mutation. Mektovi contains the active substance binimetinib.
Therapeutic Indication
Melanoma Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Non\-small cell lung cancer (NSCLC) Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with advanced non\-small cell lung cancer with a BRAF V600E mutation.
Therapeutic Area (MeSH)
ATC Code
L01EE03
ATC Item
N/A
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
EMA Name
Mektovi
Medicine Name
Mektovi
Aliases
N/ANo risk management plan link.
